dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

May 10, 2022: Immatics Biotechnologies GmbH

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

  • Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany
  • The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors
  • TCER® IMA401 targets MAGEA4/8 and will be developed in collaboration with Bristol Myers Squibb

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics’ TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8. TCER® IMA401 will be developed in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

May 9, 2022: AC Immune SA

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

First study of an anti-Abeta vaccine in people living with Down syndrome (DS)

Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine

Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.

Please read the whole article here

AC Immune SA, News 2022

May 9, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

As of 27th February 2022, Heidelberg Pharma and Huadong Medicine Co., Ltd., Hangzhou, China, (Huadong) have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement regarding an equity investment in Heidelberg Pharma. The investment by Huadong is planned in August 2022 totaling EUR 105 million, representing 35% of outstanding shares after the transaction, consisting of a rights issue and a share transfer.

Please read the whole article here
Heidelberg Pharma AG, News 2022

May 3, 2022: Cosmo Pharmaceuticals NV

COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

Cosmo Pharmaceuticals N.V. (“Cosmo”) announces the expansion of the agreement with Medtronic for the distribution of Eleview® to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022

April 28, 2022: AC Immune SA

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

Two clinical readouts delivered in Q1; five more expected by year-end

Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine

First images of alpha-synuclein in patients’ brains presented at AD/PDTM Conference provide clinical proof-of-concept for ACI-12589 as a PET tracer for alpha-synucleinopathies (e.g. MSA)

Strong financial position of CHF 173.8 million ensures the Company is fully financed through at least Q1 2024

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the quarter ended March 31, 2022, and provided a corporate update.

Please read the whole article here

AC Immune SA, News 2022

April 28, 2022: CureVac AG

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

  • Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
    – Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
    – Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
  • Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
  • Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms
  • Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer® with dedicated infrastructure and experienced management
  • Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac’s manufacturing capacity
  • Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2021 and provided a business update.

Please read the whole article here

CureVac AG, News 2022

April 28, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022

  • Start of clinical trial with HDP-101 in multiple myeloma
  • Financing commitment of up to EUR 36 million obtained from main shareholder dievini
  • Signing of a strategic partnership with Huadong Medicine with an overall volume of up to one billion US dollars
  • Financials in line with planning still without taking into account the partnership with Huadong

Heidelberg Pharma AG today reported on the first three months of fiscal year 2022 (1 December 2021 – 28 February 2022) and the Group’s financial figures.

Please read the whole article here
Heidelberg Pharma AG, News 2022

April 27, 2022: AC Immune SA

AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference, taking place virtually on April 27-28, 2022.

Please read the whole article here
AC Immune SA, News 2022

April 26, 2022: Novaliq GmbH

NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED), was presented as part of a podium symposium at the American Cataract and Refractive Surgery (ASCRS) annual meeting in Washington D.C. on April 24, 2022.

Please read the whole article here

News 2022, Novaliq GmbH

April 25, 2022: Novaliq GmbH

Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (“Bausch Health”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that data from the first pivotal Phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with´Meibomian gland dysfunction (MGD), was presented yesterday as part of a podium presentation on April 24, 2022, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C. 

Please read the whole article here

News 2022, Novaliq GmbH
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz